Dow briefly hits record high on UnitedHealth's gains
UnitedHealth Group gained 11.6 per cent to hit a more than two-month high after Warren Buffett's company revealed a new investment in the health insurer, while Michael Burry's Scion Asset Management also turned more bullish on the company.
Rising costs in the broader healthcare sector and an about 40 per cent slump in heavyweight UnitedHealth's shares this year have left the Dow lagging its Wall Street peers on the road to record highs.
The price-weighted index last scaled an all-time high on December 4.
This week, however, the healthcare sector is the top performer on the S&P 500 and is on track for its best weekly performance since October 2022.
Other insurance stocks Centene and Molina gained 5.2 per cent each.
A report showed retail sales in July rose as expected, but the University of Michigan's index tracking consumer confidence fell more than expected to 58 as inflation expectations rose.
"As long as consumer spending holds up and companies are able to retain workers because of that robust spending, the flywheel can continue to spin, pushing corporate profits and stock prices higher," said Chris Zaccarelli, chief investment officer for Northlight Asset Management, speaking on the retail sales figures.
In early trading on Friday, the Dow Jones Industrial Average rose 99.11 points, or 0.22 per cent, to 45,011.45, the S&P 500 lost 7.39 points, or 0.11 per cent, to 6,461.15 and the Nasdaq Composite lost 30.70 points, or 0.14 per cent, to 21,681.10.
Wall Street's main US stock indexes are on track for their second week of gains, buoyed by expectations that the Fed could restart its monetary policy easing cycle with a 25-basis-point interest rate cut in September.
The central bank last lowered borrowing costs in December and said US tariffs could add to price pressures.
However, recent labour market weakness and signs that tariff-induced inflation was yet to reflect in headline consumer prices have made investors confident of a potential dovish move next month.
Still, Chicago Fed President Austan Goolsbee said recent data reports showed a stagflationary impulse from tariffs on the economy.
On the trade front, US President Donald Trump said he would unveil tariffs on steel and semiconductors next week.
Applied Materials tumbled 11.3 per cent after the chip equipment maker issued weak fourth-quarter forecasts.
Intel rose 3.0 per cent after a report said the Trump administration was in talks for the US government to potentially take a stake in the chipmaker.
Attention was also on a meeting between Trump and Russian counterpart Vladimir Putin that markets hope could pave the way for a resolution to the Ukraine conflict.
Declining issues outnumbered advancers by a 1.22-to-1 ratio on the NYSE and a 1.31-to-1 ratio on the Nasdaq.
The S&P 500 posted 8 new 52-week highs and no new lows, while the Nasdaq Composite recorded 52 new highs and 45 new lows.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
7NEWS
40 minutes ago
- 7NEWS
7NEWS The Issue: Why Trump's latest veiled threat could spell trouble for the pride of Australia
It was a telling measure of the value Australians put in the country's 77-year-old Pharmaceutical Benefits Scheme. In mid March, as the Albanese government looked for an issue to give it impetus for a soon-to-be-called election, it turned to the PBS; loved in Australia - and loathed by Pharmaceutical makers abroad - for delivering medicines at little more than one quarter the cost paid by Americans. Prime Minister Albanese announced, if reelected, he'd reduce the scheme's cap on prescriptions, from $31.60 to just $25. Opposition leader Peter Dutton immediately backed the plan. 'We support affordable medicines,' he told radio 2GB. On complaints from US pharmaceutical companies about the PBS, the Prime Minister seized on the chance for a fight. The PBS, he said was 'a monument to the fairness at the heart of Australian life and we don't negotiate our values.' The PBS is political gold. Supporting it is a 'no brainer' for a federal politician. Yet, five months on that threat from the US, has only intensified and it may yet test Australia's love for the scheme. For President Donald Trump, high prescription drug costs in America have become a cause. Loading content... Last month, the White House announced the President had written to 17 drug company CEOs demanding guarantees 'they will not offer other developed nations better prices for new drugs than prices offered in the United States.' According to a Trump White House fact sheet, 'Americans are subsidising drug-manufacturer profits and foreign health systems.' The statement did not mention Australia's PBS, but if the White House staff had wanted an example, it would have been an obvious candidate. 'The PBS is a cornerstone of our Medicare system' according to Medicines Australia CEO, Liz de Somer, though that's where her applause for the scheme ends. Medicines Australia is the industry body representing many of the same pharmaceutical giants now targeted by the Trump White House. According to Liz de Somer 'we're lagging behind other countries in the time it takes to make new medicines available on the PBS.' 'We are now taking an average of 466 days for a new innovative medicine to be listed on the PBS, and that's after it's already been deemed safe and effective by the Therapeutic Goods Administration.' 'We know these drugs are safe, we know they're effective, but the government has not yet decided to purchase them and make them subsidised for patients. They take too long.' Medicines Australia wants the 466 days average drug listing time, reduced dramatically - to just sixty days. That would likely mean dramatically reducing the time taken by the government and companies to negotiate a price for their medicines. The end result could easily be a bigger bill for the Australian taxpayer. Currently, the PBS costs about $14 billion a year to run. Of course, there is a human cost to delaying approval for medicines. Medicines Australia points to the 'many, many cancer medicines that are not available for patients' in Australia. According to Liz de Somer: 'We are getting one in four innovations listed on our PBS at the moment. That's not good enough.' 'We know that people are waiting for these medicines. We know that they can see they're available in other countries, and they don't understand why they're not made available here.' There is an obvious profit motive for pharmaceutical companies in getting listed sooner and selling their product more quickly, but delays in the system have a human cost. The Albanese government is currently considering recommendations to reform the scheme including measures designed to speed the process.
AU Financial Review
14 hours ago
- AU Financial Review
Dow lifts on UnitedHealth, consumer sentiment unexpectedly falls
The Dow Jones reset a record high, while both the S&P 500 and Nasdaq Composite slipped in the final trading session of the week in New York. UnitedHealth's shares leapt more than 10 per cent after Berkshire Hathaway lifted its stake in the health insurer. That helped the Dow offset weakness in Cisco, 3M and Goldman Sachs.
Perth Now
18 hours ago
- Perth Now
Dow briefly hits record high on UnitedHealth's gains
The blue-chip Dow has briefly hit a record high, as UnitedHealth's shares jumped after Berkshire Hathaway raised its stake in the health insurer, while investors assessed mixed data to gauge the Federal Reserve's monetary policy path this year. UnitedHealth Group gained 11.6 per cent to hit a more than two-month high after Warren Buffett's company revealed a new investment in the health insurer, while Michael Burry's Scion Asset Management also turned more bullish on the company. Rising costs in the broader healthcare sector and an about 40 per cent slump in heavyweight UnitedHealth's shares this year have left the Dow lagging its Wall Street peers on the road to record highs. The price-weighted index last scaled an all-time high on December 4. This week, however, the healthcare sector is the top performer on the S&P 500 and is on track for its best weekly performance since October 2022. Other insurance stocks Centene and Molina gained 5.2 per cent each. A report showed retail sales in July rose as expected, but the University of Michigan's index tracking consumer confidence fell more than expected to 58 as inflation expectations rose. "As long as consumer spending holds up and companies are able to retain workers because of that robust spending, the flywheel can continue to spin, pushing corporate profits and stock prices higher," said Chris Zaccarelli, chief investment officer for Northlight Asset Management, speaking on the retail sales figures. In early trading on Friday, the Dow Jones Industrial Average rose 99.11 points, or 0.22 per cent, to 45,011.45, the S&P 500 lost 7.39 points, or 0.11 per cent, to 6,461.15 and the Nasdaq Composite lost 30.70 points, or 0.14 per cent, to 21,681.10. Wall Street's main US stock indexes are on track for their second week of gains, buoyed by expectations that the Fed could restart its monetary policy easing cycle with a 25-basis-point interest rate cut in September. The central bank last lowered borrowing costs in December and said US tariffs could add to price pressures. However, recent labour market weakness and signs that tariff-induced inflation was yet to reflect in headline consumer prices have made investors confident of a potential dovish move next month. Still, Chicago Fed President Austan Goolsbee said recent data reports showed a stagflationary impulse from tariffs on the economy. On the trade front, US President Donald Trump said he would unveil tariffs on steel and semiconductors next week. Applied Materials tumbled 11.3 per cent after the chip equipment maker issued weak fourth-quarter forecasts. Intel rose 3.0 per cent after a report said the Trump administration was in talks for the US government to potentially take a stake in the chipmaker. Attention was also on a meeting between Trump and Russian counterpart Vladimir Putin that markets hope could pave the way for a resolution to the Ukraine conflict. Declining issues outnumbered advancers by a 1.22-to-1 ratio on the NYSE and a 1.31-to-1 ratio on the Nasdaq. The S&P 500 posted 8 new 52-week highs and no new lows, while the Nasdaq Composite recorded 52 new highs and 45 new lows.
